<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38454352</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Post-recovery health domain scores among outpatients by SARS-CoV-2 testing status during the pre-Delta period.</ArticleTitle><Pagination><StartPage>300</StartPage><MedlinePgn>300</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">300</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09108-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Symptoms of COVID-19 including fatigue and dyspnea, may persist for weeks to months after SARS-CoV-2 infection. This study compared self-reported disability among SARS-CoV-2-positive and negative persons with mild to moderate COVID-19-like illness who presented for outpatient care before widespread COVID-19 vaccination.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Unvaccinated adults with COVID-19-like illness enrolled within 10&#x2009;days of illness onset at three US Flu Vaccine Effectiveness Network sites were tested for SARS-CoV-2 by molecular assay. Enrollees completed an enrollment questionnaire and two follow-up surveys (7-24&#x2009;days and 2-7&#x2009;months after illness onset) online or by phone to assess illness characteristics and health status. The second follow-up survey included questions measuring global health, physical function, fatigue, and dyspnea. Scores in the four domains were compared by participants' SARS-CoV-2 test results in univariate analysis and multivariable Gamma regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During September 22, 2020 - February 13, 2021, 2712 eligible adults were enrolled, 1541 completed the first follow-up survey, and 650 completed the second follow-up survey. SARS-CoV-2-positive participants were more likely to report fever at acute illness but were otherwise comparable to SARS-CoV-2-negative participants. At first follow-up, SARS-CoV-2-positive participants were less likely to have reported fully or mostly recovered from their illness compared to SARS-CoV-2-negative participants. At second follow-up, no differences by SARS-CoV-2 test results were detected in the four domains in the multivariable model.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Self-reported disability was similar among outpatient SARS-CoV-2-positive and -negative adults 2-7&#x2009;months after illness onset.</AbstractText><CopyrightInformation>&#xa9; 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>King</LastName><ForeName>Jennifer P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, 1000 North Oak Avenue ML2, Marshfield, WI, 54449, USA. King.jennifer@marshfieldresearch.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Jessie R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Influenza Division, US Centers for Disease Control and Prevention, 1600 Clifton Rd, Mailstop H24-7, Atlanta, GA, 30329, USA. jchung@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donahue</LastName><ForeName>James G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, 1000 North Oak Avenue ML2, Marshfield, WI, 54449, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Emily T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leis</LastName><ForeName>Aleda M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monto</LastName><ForeName>Arnold S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaglani</LastName><ForeName>Manjusha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Baylor Scott &amp; White Health, Temple, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Texas A&amp;M University College of Medicine, Temple, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunnigan</LastName><ForeName>Kayan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Baylor Scott &amp; White Research Institute, Temple, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raiyani</LastName><ForeName>Chandni</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Baylor Scott &amp; White Research Institute, Temple, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saydah</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Coronavirus and Other Respiratory Viruses Division, US Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flannery</LastName><ForeName>Brendan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Influenza Division, US Centers for Disease Control and Prevention, 1600 Clifton Rd, Mailstop H24-7, Atlanta, GA, 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belongia</LastName><ForeName>Edward A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, 1000 North Oak Avenue ML2, Marshfield, WI, 54449, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 DK020572</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 condition</Keyword></KeywordList><CoiStatement>ETM has received research funds from Merck for unrelated work. All other authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>0</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38454352</ArticleId><ArticleId IdType="pmc">PMC10921777</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09108-3</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09108-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region - case series. N Engl J Med. 2020;382(21):2012&#x2013;2022. doi: 10.1056/NEJMoa2004500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2004500</ArticleId><ArticleId IdType="pmc">PMC7143164</ArticleId><ArticleId IdType="pubmed">32227758</ArticleId></ArticleIdList></Reference><Reference><Citation>US Centers for Disease Control and Prevention. Symptoms of COVID-19 2022 updated Oct 26,2022. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinicalMedicine. 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie CE, Lowe DJ, McAuley A, Winter AJ, Mills NL, Black C, et al. Outcomes among confirmed cases and a matched comparison group in the long-COVID in Scotland study. Nat Commun. 2022;13(1):5663. doi: 10.1038/s41467-022-33415-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33415-5</ArticleId><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>US Centers for Disease Control and Prevention. Long COVID or Post-COVID conditions 2022 [updated December 16, 2022]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>Robertson MM, Qasmieh SA, Kulkarni SG, Teasdale CA, Jones HE, McNairy M, et al. The epidemiology of long coronavirus disease in US adults. Clin Infect Dis. 2023;76(9):1636&#x2013;1645. doi: 10.1093/cid/ciac961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac961</ArticleId><ArticleId IdType="pubmed">36542514</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rensen AIV, Spiliopoulos L, Bager P, Nielsen NM, Hansen JV, Koch A, et al. A nationwide questionnaire study of post-acute symptoms and health problems after SARS-CoV-2 infection in Denmark. Nat Commun. 2022;13(1):4213. doi: 10.1038/s41467-022-31897-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31897-x</ArticleId><ArticleId IdType="pmc">PMC9302226</ArticleId><ArticleId IdType="pubmed">35864108</ArticleId></ArticleIdList></Reference><Reference><Citation>Atchison CJ, Davies B, Cooper E, Lound A, Whitaker M, Hampshire A, et al. Long-term health impacts of COVID-19 among 242,712 adults in England. Nat Commun. 2023;14(1):6588. doi: 10.1038/s41467-023-41879-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41879-2</ArticleId><ArticleId IdType="pmc">PMC10598213</ArticleId><ArticleId IdType="pubmed">37875536</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020;8:8. doi: 10.1038/s41413-020-0084-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41413-020-0084-5</ArticleId><ArticleId IdType="pmc">PMC7018717</ArticleId><ArticleId IdType="pubmed">32128276</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L, Baca S, Saydah S, Boehmer TK, Adjei S, Gray S, Harris AM. Post&#x2013;COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years &#x2014; United States, march 2020&#x2013;November 2021. Morb Mortal Wkly. 2022;71(21):713&#x2013;717. doi: 10.15585/mmwr.mm7121e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Devine OJ, Reese HE, Silk BJ, Iuliano AD, Threlkel R, et al. Point prevalence estimates of activity-limiting long-term symptoms among United States adults &#x2265;1 month after reported severe acute respiratory syndrome coronavirus 2 infection, 1 November 2021. J Infect Dis. 2022;227(7):855&#x2013;863. doi: 10.1093/infdis/jiac281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac281</ArticleId><ArticleId IdType="pmc">PMC9278232</ArticleId><ArticleId IdType="pubmed">35776165</ArticleId></ArticleIdList></Reference><Reference><Citation>House W. COVID-19 press briefing 2021 updated November 10. 2021.</Citation></Reference><Reference><Citation>National Center for Health Statistics. U.S. Census Bureau. Household Pulse Survey, 2022-2023. Long COVID 2023 [updated May 17, 2023]. Available from: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm.</Citation></Reference><Reference><Citation>National Academy for State Health Policy. States&#x2019; COVID-19 Public Health Emergency Declarations 2023 [updated June 13, 2023]. Available from: https://nashp.org/states-covid-19-public-health-emergency-declarations/.</Citation></Reference><Reference><Citation>Chung JR, Kim SS, Jackson ML, Jackson LA, Belongia EA, King JP, et al. Clinical symptoms among ambulatory patients tested for SARS-CoV-2. Open forum. Infect Dis. 2021;8(1):ofaa576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717425</ArticleId><ArticleId IdType="pubmed">33537361</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafer L, Ahmed F, Kim S, Wernli KJ, Jackson ML, Nowalk MP, et al. Relationship between telework experience and Presenteeism during COVID-19 pandemic, United States, march-November 2020. Emerg Infect Dis. 2023;29(2):278&#x2013;285. doi: 10.3201/eid2902.221014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2902.221014</ArticleId><ArticleId IdType="pmc">PMC9881775</ArticleId><ArticleId IdType="pubmed">36599411</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food &amp; Drug Administration. Access SARS-CoV-2 IgG Instructions for Use 2021 Available from: https://www.fda.gov/media/139627/download.</Citation></Reference><Reference><Citation>Bingham Iii CO, Gutierrez AK, Butanis A, Bykerk VP, Curtis JR, Leong A, et al. PROMIS fatigue short forms are reliable and valid in adults with rheumatoid arthritis. J Patient Rep Outcomes. 2019;3(1):14. doi: 10.1186/s41687-019-0105-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41687-019-0105-6</ArticleId><ArticleId IdType="pmc">PMC6384289</ArticleId><ArticleId IdType="pubmed">30790155</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen RE, Potosky AL, Reeve BB, Hahn E, Cella D, Fries J, et al. Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients. Qual Life Res. 2015;24(10):2333&#x2013;2344. doi: 10.1007/s11136-015-0992-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-015-0992-9</ArticleId><ArticleId IdType="pmc">PMC5079641</ArticleId><ArticleId IdType="pubmed">25935353</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook KF, Jensen SE, Schalet BD, Beaumont JL, Amtmann D, Czajkowski S, et al. PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions. J Clin Epidemiol. 2016;73:89&#x2013;102. doi: 10.1016/j.jclinepi.2015.08.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.08.038</ArticleId><ArticleId IdType="pmc">PMC5131708</ArticleId><ArticleId IdType="pubmed">26952842</ArticleId></ArticleIdList></Reference><Reference><Citation>Schalet BD, Hays RD, Jensen SE, Beaumont JL, Fries JF, Cella D. Validity of PROMIS physical function measured in diverse clinical samples. J Clin Epidemiol. 2016;73:112&#x2013;118. doi: 10.1016/j.jclinepi.2015.08.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.08.039</ArticleId><ArticleId IdType="pmc">PMC4968197</ArticleId><ArticleId IdType="pubmed">26970039</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella D, Lai JS, Jensen SE, Christodoulou C, Junghaenel DU, Reeve BB, Stone AA. PROMIS fatigue item Bank had clinical validity across diverse chronic conditions. J Clin Epidemiol. 2016;73:128&#x2013;134. doi: 10.1016/j.jclinepi.2015.08.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.08.037</ArticleId><ArticleId IdType="pmc">PMC4902759</ArticleId><ArticleId IdType="pubmed">26939927</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose M, Bjorner JB, Gandek B, Bruce B, Fries JF, Ware JE., Jr The PROMIS physical function item bank was calibrated to a standardized metric and shown to improve measurement efficiency. J Clin Epidemiol. 2014;67(5):516&#x2013;526. doi: 10.1016/j.jclinepi.2013.10.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2013.10.024</ArticleId><ArticleId IdType="pmc">PMC4465404</ArticleId><ArticleId IdType="pubmed">24698295</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella D, Choi SW, Condon DM, Schalet B, Hays RD, Rothrock NE, et al. PROMIS(&#xae;) adult health profiles: efficient short-form measures of seven health domains. Value Health. 2019;22(5):537&#x2013;544. doi: 10.1016/j.jval.2019.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2019.02.004</ArticleId><ArticleId IdType="pmc">PMC7201383</ArticleId><ArticleId IdType="pubmed">31104731</ArticleId></ArticleIdList></Reference><Reference><Citation>Garson GD. Generalized linear models / generalized estimating equations. 2013. Asheboro, NC: Statistical Associates Publishers; 2013.</Citation></Reference><Reference><Citation>Gottlieb M, Wang RC, Yu H, Spatz ES, Montoy JCC, Rodriguez RM, et al. Severe fatigue and persistent symptoms at 3 months following severe acute respiratory syndrome coronavirus 2 infections during the Pre-Delta, Delta, and omicron time periods: a multicenter prospective cohort study. Clin Infect Dis. 2023;76(11):1930&#x2013;1941. doi: 10.1093/cid/ciad045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad045</ArticleId><ArticleId IdType="pmc">PMC10249989</ArticleId><ArticleId IdType="pubmed">36705268</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M, Mercad&#xe9;-Besora N, Kolde R, Trinh NTH, Roel E, Burn E, et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med. 2024;</Citation><ArticleIdList><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, Th&#xe5;lin C. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. Jama. 2021;325(19):2015&#x2013;2016. doi: 10.1001/jama.2021.5612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.5612</ArticleId><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, march-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993&#x2013;998. doi: 10.15585/mmwr.mm6930e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh R, Ghosh AK, Nyman MA, Croghan IT, Grach SL, Anstine CV, et al. PROMIS scales for assessment of persistent post-COVID symptoms: a cross sectional study. J Prim Care Community Health. 2021;12:21501327211030413. doi: 10.1177/21501327211030413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/21501327211030413</ArticleId><ArticleId IdType="pmc">PMC8267017</ArticleId><ArticleId IdType="pubmed">34231395</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Romieu AC, Carton TW, Saydah S, Azziz-Baumgartner E, Boehmer TK, Garret NY, et al. Prevalence of select new symptoms and conditions among persons aged younger than 20 years and 20 years or older at 31 to 150 days after testing positive or negative for SARS-CoV-2. JAMA Netw Open. 2022;5(2):e2147053. doi: 10.1001/jamanetworkopen.2021.47053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.47053</ArticleId><ArticleId IdType="pmc">PMC8817203</ArticleId><ArticleId IdType="pubmed">35119459</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvakumar J, Havdal LB, Drevvatne M, Brodwall EM, Lund Berven L, Stiansen-Sonerud T, et al. Prevalence and characteristics associated with post-COVID-19 condition among nonhospitalized adolescents and young adults. JAMA Netw Open. 2023;6(3):e235763. doi: 10.1001/jamanetworkopen.2023.5763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.5763</ArticleId><ArticleId IdType="pmc">PMC10064252</ArticleId><ArticleId IdType="pubmed">36995712</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisk LE, Gottlieb MA, Spatz ES, Yu H, Wang RC, Slovis BH, et al. Association of Initial SARS-CoV-2 test positivity with patient-reported well-being 3 months after a symptomatic illness. JAMA Netw Open. 2022;5(12):e2244486. doi: 10.1001/jamanetworkopen.2022.44486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.44486</ArticleId><ArticleId IdType="pmc">PMC9716377</ArticleId><ArticleId IdType="pubmed">36454572</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher KA, Olson SM, Tenforde MW, Self WH, Wu M, Lindsell CJ, et al. Symptoms and recovery among adult outpatients with and without COVID-19 at 11 healthcare facilities-July 2020, United States. Influenza Other Respir Viruses. 2021;15(3):345&#x2013;351. doi: 10.1111/irv.12832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12832</ArticleId><ArticleId IdType="pmc">PMC8051737</ArticleId><ArticleId IdType="pubmed">33405338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed F, Kim S, Nowalk MP, King JP, VanWormer JJ, Gaglani M, et al. Paid leave and access to telework as work attendance determinants during acute respiratory illness, United States, 2017-2018. Emerg Infect Dis. 2020;26(1):26&#x2013;33. doi: 10.3201/eid2601.190743.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2601.190743</ArticleId><ArticleId IdType="pmc">PMC6924903</ArticleId><ArticleId IdType="pubmed">31855145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28(5):911&#x2013;923. doi: 10.1038/s41591-022-01810-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10(9):863&#x2013;876. doi: 10.1016/S2213-2600(22)00126-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang MC, Chung JR, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Fry AM, Flannery B. Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016. Vaccine. 2018;36(52):8047&#x2013;8053. doi: 10.1016/j.vaccine.2018.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.10.093</ArticleId><ArticleId IdType="pmc">PMC6282182</ArticleId><ArticleId IdType="pubmed">30420119</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>